Partnering Interests
Partnering Interests
Search
Championing for people with all abilities
Every diverse background brings unique perspectives to our company.
Scleroderma
Scleroderma
Company History | Corporate Profile | Boehringer Ingelheim US
Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
Fornovo San Giovanni (Bidachem)
Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health
Focus on Alliance Management
Focus on Alliance Management
Companion Animals & Horses
Companion Animals & Horses
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Patient Week 2024 demonstrates importance of #PatientPoweredProgress
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US
Click here to read more on the launch of the new Bovikalc® Dry for Dairy Cows, an oral mineral supplement contributing to well-being for dairy cows.
CIA Reporting Requirements
CIA Reporting Requirements
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Striving to revolutionize mental health research
World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
Pioneers who inspire: Women in livestock
Pioneers who inspire: Women in livestock
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease
Pushing for Progress
Pushing for Progress
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Sarcoma: An expert’s perspective
Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.